Organic Active Ingredients TRIZ Cases

Palladium-catalyzed thienopyrimidine synthesis achieves selective Class Ia PI3K inhibition, resolving broad kinase activity trade-offs.

Inhibiting biliverdin IXβ reductase increases platelet counts while avoiding thromboembolic complications linked to TPO axis targeting.

Substituted pyridopyrimidines target specific PI3K isoforms to overcome the poor selectivity of first-generation kinase inhibitors.

A metallo-lactoferrin and coenzyme composition triggers intracellular adenosine triphosphate release through proton gradient recreation.

Antisense oligonucleotides block exon junction complex deposition to stabilize mRNA transcripts.

Crystalline salt forms of a pyrimidine derivative enhance bioavailability, resolving formulation complexity while improving therapeutic efficacy.

Fused pyrroledicarboxamides inhibit TASK-1 channels to treat arrhythmias while avoiding hERG-mediated cardiotoxicity.

An osmotic pump system delivers nifedipine over 24 hours while an outer coating releases angiotensin-II antagonists rapidly to stabilize plasma levels.

Nanoparticles coated with cationic polymers and stabilizers deliver antigens to stimulate immune responses.

Sulfonamide derivatives with fused pyrimidine skeletons suppress cancer cell growth driven by EGFR mutations while minimizing side effects on normal cells.

FLT3 receptor antagonists block nociceptor sensitivity to alleviate neuropathic pain symptoms.

A coacervate system delivers cytokines via localized sustained release.

Phytate adsorbs onto calcium phosphate crystals to stabilize bone mineral, addressing the bottleneck of existing crystal dissolution in osteoporosis treatment.

Targeted pharmacological regimens prevent transplanted xenogeneic organs from overgrowing within recipient primates, ensuring stable long-term function.

Creatine kinase derived peptides isolate analgesic activity from harmful side effects to reverse neuropathic pain.

Novel compounds bind wild-type and mutant PKR to induce tetramer formation, treating pyruvate kinase deficiency without invasive surgery.

5α-androstane-3β,5,6β-triol reduces vasogenic edema and neuronal degeneration caused by hypobaric hypoxia.

Ginseng berry extract stimulates nitric oxide generation to improve blood circulation and enhance endothelial cell viability.

Co-administering a c-Met/EGFR dual inhibitor with an IGF-1R inhibitor to simultaneously target multiple oncogenic pathways.

Small extracellular vesicles deliver specific microRNAs to regulate PTX3 expression levels in therapeutic agents.

Oxygen scavengers and pH adjustment prevent oxidation and deacetylation, maintaining injectable paracetamol stability in plastic containers.

Mechanical extrusion detaches stromal precursor cells from collagen matrices, eliminating enzymatic treatments that increase clinical trial duration.

Chitosan nanoparticles encapsulate anti-galectin-1 siRNA for intranasal delivery across the blood-brain barrier.

Macroporous resin adsorption isolates high-acetyl monomeric polysaccharide ME-2, preserving structural integrity while removing proteins and pigments.

Lipid nanoparticle formulations protect nucleic acids from enzymatic degradation while achieving high transfection efficiency and targeted release.

Smad3 inhibitors target the TGF-beta pathway to reduce severe side effects while effectively suppressing tumor growth and invasion.

Benzylamino substituted pyridopyrimidinones bind the SOS1 catalytic site to block RAS-family protein interactions.

Segmenting the molecule into functional modules resolves targeting difficulty while maintaining therapeutic effectiveness for lung and colon cancers.

AICAr triggers LRRK2 mRNA decay to lower toxic protein levels, addressing delayed onset and side effects of current therapies.

Tetraaza-cyclopentaindenyl compounds act as positive allosteric modulators at the muscarinic M1 receptor.

Pharmaceutical compositions inhibit CD44-Moesin binding via small molecules, reducing neuroinflammation and protecting neurons from necroptosis.

Parthenolide analogues target NF-kB signaling pathways to eliminate chemotherapy-resistant cancer stem cells and reverse tumor recurrence.

Coaxial counter-rotating rotors compensate for torque to enable vertical flight, reducing mechanical complexity compared to conventional helicopters.

Asymmetric needle tip deflects off choroid tissue to prevent trauma while delivering thixotropic drug formulations into suprachoroidal space.

Novel oxazepine compounds selectively inhibit late sodium currents to treat cardiovascular diseases and diabetes.

A cationic polymeric matrix forms stable complexes with negatively charged macromolecules to enhance mucosal absorption.

A pharmaceutical composition combining cilostazol and edaravone treats cerebrovascular diseases through synergistic therapeutic mechanisms.

Ibuprofen hybrid conjugates link the drug to amino acids or 4-aminophenol, reducing ulcerogenic effects while maintaining anti-inflammatory efficacy.

A Cholix-derived carrier binds therapeutic proteins to internalize them via receptor-mediated endocytosis.

Specific heteroaryl compounds constrain Bcl-xL proteins to trigger apoptosis in cancer cells while sparing normal cell toxicity.

Biodegradable particles deliver cytokine-antibody fusion proteins to selectively expand antigen-specific regulatory T cells, avoiding broad immunosuppression.

Segmented transdermal patches maintain steady serum levels to eliminate withdrawal bleeding and adverse events from oral dosing interruptions.

Polysubstituted imidazopyridine compounds enhance therapeutic efficacy and specificity by targeting Nurr-1 nuclear receptors for disease treatment.

A wet granulation process using dibasic calcium phosphate and microcrystalline cellulose creates stable levetiracetam tablets.

A 1H-NMR method using dimethylmalonic acid as an internal standard quantifies glycosaminoglycan signals for accurate monosaccharide composition analysis.

Isolating brown adipocyte progenitors from adult human skeletal muscle enables targeted therapeutic intervention for obesity and type 2 diabetes.

Hybridizing guide RNA targets specific viral DNA for Cas9-mediated excision, reducing HIV-1 burden while minimizing cytotoxicity to uninfected cells.

Fused bicyclic compounds inhibit both mTORC1 and mTORC2 complexes, overcoming partial efficacy and resistance seen with rapamycin analogues.

Pyridine derivatives balance inhibitory efficacy with druggability, solubility, permeability, and metabolic stability for treating ASK1-associated diseases.

Cholesterol-conjugated siRNA targets myostatin via systemic injection, resolving the trade-off between delivery efficiency and invasive pain in muscle therapy.

Albumin-bound paclitaxel nanoparticles target tumors via SPARC binding, reducing hypersensitivity reactions.

Synthetic metal complexes overcome natural enzyme limitations by providing oral bioavailability, extended half-life, and reduced immunogenicity.

Pyrazolo-pyrazine derivatives maintain inhibition strength against mutated ROS1 kinases by altering binding affinity parameters.

Classifier analyzes PBXIP1, ETS1, and ANGPTL3 protein activity to predict fimepinostat response in MYC-altered DLBCL patients.

Beta-glucan compounds bind to B cells via covalent or affinity linkages to modulate biological functions.

Segmented pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridine scaffolds overcome drug resistance in cancer cells.

Magnetic nanoparticles guide therapeutic agents through dentinal tubules to treat pulpitis, avoiding invasive root canal procedures.

Merging Raf kinase inhibition with taxane microtubule stabilization reduces peripheral neuropathy while extending therapeutic response duration.

CRHR1 antagonists block inflammatory processes to reduce endometriotic vesicle size, addressing inadequate long-term symptom management.

Computational inhibitors target extended-alpha-strand regions of amyloidogenic proteins to prevent aggregation into toxic fibrils.

Pyrrolopyrimidine compounds block BAFF-induced IL-6 production, addressing ineffective autoimmune response management in Sjögren syndrome.

Boronic acid polymers form reversible covalent linkages with polyols, reducing nonspecific binding and degradation of therapeutic agents.

L-alanyl-L-glutamine in the perfusate releases glutamine to protect corneal endothelial cells from apoptosis and mechanical damage.

Novel compounds selectively inhibit PI3K isoforms to treat cancer and inflammatory disorders.

Optimized triazoloquinazoline structures resolve the contradiction between high CDK inhibition activity and reduced toxicity in solid tumor treatments.

N1- and N7-substituted sibiriline derivatives resolve stability limitations of existing inhibitors by targeting RIPK1 to reduce off-target toxicity.

Sterile tiotropium solution removes benzalkonium chloride to prevent paradoxic bronchoconstriction.

Solid concentrate tablets replace liquid storage, enabling on-demand dialysate preparation that minimizes waste and reduces required storage space.

Polyvinylpyrrolidone prevents amorphous sitagliptin crystallization, resolving bioavailability and stability trade-offs.

Anthraquinone dyes and titanium dioxide in a polyester container block 190-750 nm light, reducing melatonin photodegradation loss to under 30% after 100 days.

Amphipathic molecules self-assemble into stable core-shell nanostructures that remove excess cholesterol, resolving size distribution and stability trade-offs.

Antibodies bind circulating Reelin protein to reduce leukocyte adhesion, attenuating atherosclerotic lesion development and plaque rupture risk.

Nicotinamide mononucleotide derivatives protect cardiac tissue through mitochondrial enhancement.

A salt content of 3.0% to 4.5% by weight in an oral composition achieves a neutral taste characteristic while maintaining sufficient flavor intensity.

An antimicrobial actuator within a catheter side port mechanically collapses tubing to open flowpaths and elutes agents into residual fluid.

Targeting DHHC3 suppresses PD-L1 through CMTM6 palmitoylation, overcoming tumor resistance to immune checkpoint blockade.

Centrosome clustering inhibitors eliminate cells with excess centrosomes, reducing cyst formation and fibrosis while preserving renal function.

Ligands targeting ASP32 reduce amyloid beta levels while minimizing harmful side effects.

Spray-drying aqueous human milk oligosaccharides converts them into amorphous powders with elevated glass transition temperatures.

Hydroxylated elovanoid derivatives protect neural tissue and restore organ function through targeted lipid metabolism pathways.

Mutant Hsp70 proteins enhance microautophagy activity to clear aggregates, addressing selective motor neuron vulnerability in SMA and ALS models.

A transdermal patch uses free ropinirole dissolved in a styrene-isoprene-styrene adhesive base with rosin-based resin.

Selective SUV39H1 inhibitors reduce tumor burden in colorectal and pancreatic cancers by reversing epigenetic resistance to immunotherapy.

A mucoadhesive oral patch delivers tetracaine and triamcinolone via a bilayer film to extend residence time and reduce administration frequency.

Gunagratinib targets FGFR signaling aberrations to manage disease progression in squamous cell carcinomas.

Double-stranded nucleic acid inhibitor molecules incorporate Tm-increasing nucleotides within the stem loop structure to enhance thermal stability and duration of activity.

Barbituric acid derivatives inhibit topoisomerase IIα to induce apoptosis in tumor cells.

A segmented oral dosage form uses a semipermeable membrane and water-swellable excipients to deliver GABAB receptor agonists via osmosis.

A film-forming polymer and non-aqueous vehicle composition adheres to oral surfaces.

Measuring H3K27me3 and E-cadherin levels predicts cancer responsiveness to immunotherapeutic agents.

Histidine-acetate buffer at pH 5.5 to 6.5 stabilizes monoclonal antibodies against deamidation and aggregation.

Converting amorphous furopyrimidine to crystalline hydrochloride or methanesulfonate salts resolves low water solubility and poor stability.

Double-stranded RNA targets mutant EGFR transcripts to inhibit gene expression while sparing wild-type receptors.

Auraptene analogs replace unstable BMP-2 to promote osteoblast differentiation while maintaining safety and stability.